4] Nonstandard abbreviations: CD40L, CD40 ligand; sCD40L, soluble CD40L; PCI, percutaneous coronary intervention; ACS, acute coronary syndrome; [beta]TG, [beta]-thromboglobulin; PF4, platelet factor
4; CTAD, citrate, theophylline, adenosine, and dipyridamole; PPP, platelet-poor plasma.
Diagnostic testing for heparin-induced thrombocytopenia (HIT): an enhanced platelet factor
4 complex enzyme linked immunosorbent assay (PF4 ELISA).
Low molecular weight heparins contain that sequence, so their binding is specific to antithrombin and they are less susceptible to interfering substances such as endothelium, platelets, platelet factor
IV, and plasma proteins.
Further evidence that alpha-granule components such as platelet factor 4 are involved in platelet-IgG-heparin interactions during heparin-associated thrombocytopenia.
Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases.
Platelet factor 4, [beta]-thromboglobulin, and serotonin are specific products of platelets that are released on the activation of platelets (20).
2], FPA, platelet factor 4, and D-dimer have provided useful information for the differential diagnosis of the hypercoagulable state and thrombotic response during MI.
One of the patents covers radiopharmaceuticals comprising peptides derived from platelet factor 4, which is known to attract and bind with white blood cells.
P483H combines a polybasic platelet factor 4-derived peptide compound with heparin, a polysulfated glycan.
CAMBRIDGE, Mass, April 17 /PRNewswire/ -- Researchers from the University of North Carolina at Chapel Hill School of Medicine (UNC-CH) and Repligen Corporation (Nasdaq: RGEN) reported that Repligen's recombinant platelet factor four (rPF4) appears to be effective at restoring coagulation by reversing the effects of heparin, an anticoagulant that is used following cardiovascular procedures.
The UNC-CH/Repligen Phase I trial results appear in the April 15, 1995 issue of the scientific journal Circulation article "Reversal of Heparin Anticoagulation by Recombinant Platelet Factor 4 in Humans.
related to the development program for recombinant platelet factor
- 4 (rPF4).